HIPGEN-801653 Improved MSC Minimal Criteria to Maximize Patient Safety: A Call to Embrace Tissue Factor and Hemocompatibility Assessment of MSC Products

Summary

This is a publication. If there is no link to the publication on this page, you can try the pre-formated search via the search engines listed on this page.

Authors: Guido Moll, James A. Ankrum, Scott D. Olson, Jan A. Nolta

Journal title: Stem Cells Translational Medicine

Journal publisher: AlphaMed Press

Published year: 2022

DOI identifier: 10.1093/stcltm/szab005

ISSN: 2157-6564

Associated projects

$Placenta-expanded adherent stromal cells (PLX-PAD) as an innovative therapy for improving recovery and survival following hip fracture arthroplasty – HIPGEN, a multicenter phase III trial$ HIPGEN - Placenta-expanded adherent stromal cells (PLX-PAD) as an innovative therapy for improving recovery and survival following hip fracture arthroplasty – HIPGEN, a multicenter phase III trial

Organisations

Not specified